Tomorrow’s
News Sponsored by British breakthrough provides lasting
protection GermErase, a new brand at the frontline of protecting against COVID-19, infections and superbugs, has launched its first products range, guaranteeing the highest levels of protection against pathogens for up to a month.
GermErase is the first and only multi-surface protector proven to kill SARS-CoV-2 in under 30 seconds, and a broad range of other pathogens, with up to 99.9999% efficacy, making it faster and more effective than any other product currently available on the market. Unlike any other brand in the UK, it is the first British product to be tested against SARS-CoV-2, the virus that causes COVID-19, as opposed to proxy viruses which is how most products have been tested.
GermErase, which is available as a multi-surface cleaning spray and hand spray with wipes, provides a protective barrier against bacteria and viruses up to 48 hours. Bonding to any treated surface, it remains effective at log-4 for 28 days.
While alcohol gels and sanitisers are dependent on concentration levels and a lengthy period of application for the best results against SARS-CoV-2, GermErase is easy to use and completely kills the virus within seconds with a simple spray.
The product range has been tested to global standards in independent facilities at the University of Southampton, including on live strains of SARS-Cov-2.
At 99.9% water, GermErase is very safe and has low toxicity. It uses common ingredients that have already been approved for medical and cleaning purposes and is ready
to distribute at scale across the country exclusively via specialist cleaning supplier, Denis Rawlins.
The products can be used by medical professionals in hospitals but are also quick and easy to use by private sector businesses – giving employers and employees the confidence to return to work safely and unlock the economic recovery in the UK. GermErase will launch a consumer product range for the general public in Spring 2021.
Matthew Higdon, Chairman of GermErase, commented: “Our intention is for GermErase to become the first line of defence against infection for hospitals, businesses and families across the country. This product will allow us to get our freedom back and live with peace of mind that we are protected against pathogens like SARS-CoV-2. Our ambition is for this British breakthrough to represent a landmark moment in the fightback against COVID-19, infections and superbugs.”
James White, MD of Denis Rawlins, added: “As we continue to battle against COVID-19, our priority is delivering the most robust and effective cleaning solutions to our customer base. GermErase provides a far superior result than anything else we have seen on the market and we were very impressed by the brand’s efficacy, contact time and cost-in-use credentials. We are delighted to be promoting the brand and are confident that it will help our customers, and their clients, get back to work quickly.”
Professor Bill Keevil, Professor of Environmental Healthcare at the University of Southampton, added: “An invention like this does not come across your desk very often. We have found that GermErase demonstrates remarkable breadth of efficacy against bacteria and viruses, speed of kill, residual efficacy and shows no evidence of antimicrobial resistance.”
www.rawlins.co.uk
10 | WHAT’S NEW?
twitter.com/TomoCleaning
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
